ABCL NASDAQ
AbCellera Biologics Inc.
1W: +16.8%
1M: +26.0%
3M: +69.1%
YTD: +49.9%
1Y: +145.9%
3Y: -9.8%
5Y: -83.8%
$5.20
+0.06 (+1.17%)
Weekly Expected Move ±11.9%
$3
$4
$4
$5
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$1.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range1.94-6.515
Volume6,433,629
Avg Volume5,513,487
Beta1.03
Dividend—
Analyst Ratings
Company Info
CEOCarl Hansen
Employees596
SectorHealthcare
IndustryBiotechnology
IPO Date2020-12-11
Websiteabcellera.com
2215 Yukon Street
Vancouver, BC V5Y 0A1
CA
Vancouver, BC V5Y 0A1
CA
604 559 9005
About AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Latest News
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
ABCL Stock Climbs As Earnings Beat, Drug Data Fuel Bullish Outlook - StocksToTrade
$ABCL stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
$ABCL stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
ABCL stock clocks best week since February on clinical data anticipation, Baker Bros stake boost - MSN
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Montalbano John S. | P-Purchase | 20,000 | $4.77 | 2026-05-14 |
| Thermopylae Holdings | P-Purchase | 38,000 | $3.44 | 2026-02-27 |
| Booth Andrew | P-Purchase | 42,600 | $3.42 | 2026-02-27 |
| Thermopylae Holdings | P-Purchase | 177,457 | $3.27 | 2026-02-26 |
| Booth Andrew | A-Award | 808,898 | $3.42 | 2026-01-01 |